{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.23","value":"17.8"},{"groupId":"OG001","spread":"28.77","value":"16.0"},{"groupId":"OG002","spread":"27.02","value":"16.1"}]}],"title":"Interfered with general activity"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.03","value":"18.3"},{"groupId":"OG001","spread":"29.44","value":"17.8"},{"groupId":"OG002","spread":"34.62","value":"18.9"}]}],"title":"Interfered with mood"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.15","value":"11.0"},{"groupId":"OG001","spread":"18.16","value":"6.0"},{"groupId":"OG002","spread":"22.17","value":"9.1"}]}],"title":"Interfered with normal work"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"37.41","value":"23.0"},{"groupId":"OG001","spread":"33.02","value":"18.5"},{"groupId":"OG002","spread":"41.15","value":"24.3"}]}],"title":"Interfered with relations with other people"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.27","value":"5.6"},{"groupId":"OG001","spread":"12.75","value":"5.1"},{"groupId":"OG002","spread":"21.99","value":"10.8"}]}],"title":"Interfered with sleep"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.17","value":"26.7"},{"groupId":"OG001","spread":"36.11","value":"21.1"},{"groupId":"OG002","spread":"33.14","value":"30.2"}]}],"title":"Interfered with enjoyment of life"}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"58"},{"groupId":"OG002","value":"54"}],"units":"Participants"}],"description":"The impact of vaginal dryness for activities of daily living (ADL) were measured by the numerical analogue scales at baseline and through the six weeks of treatment. The item scores was transformed into 0 to 100 scales with 0=poor quality of life (QOL) and 100=best possible QOL. The change from baseline scores was calculated by subtracting the baseline item scores from the scores at 6 week.","dispersionType":"Standard Deviation","groups":[{"description":"Patients receive 1 capsule of placebo 2 times per day for 6 weeks and; patients receive 1 capsule of placebo 4 times per day for 6 weeks.","id":"OG000","title":"Collective Placebo"},{"description":"Patients receive 5mg of Pilocarpine 2 times per day for 6 weeks.","id":"OG001","title":"Pilocarpine 2 Times Per Day"},{"description":"Patients receive 5mg of Pilocarpine 4 times per day for 6 weeks.","id":"OG002","title":"Pilocarpine 4 Times Per Day"}],"paramType":"MEAN","populationDescription":"Includes all participants who completed both baseline and week 6 assessments.","reportingStatus":"POSTED","timeFrame":"Baseline and Week 6","title":"Change From Baseline to Week 6 on the Impact of Vaginal Dryness for Activities of Daily Living Scores","type":"SECONDARY","unitOfMeasure":"units on a scale"}